TransCon CNP

Designed for continuous CNP exposure to rebalance bone growth in skeletal disorders

Designed for continuous CNP exposure to rebalance bone growth in skeletal disorders

Vector-Smart-Object-copy

TransCon technology has extended exposure of CNP from 2.5 minutes to 120 hours - unlocking its therapeutic potential to pursue a new frontier of growth biology.

Explore

You are about to access www.ascendispharma.us.
The information on this website is intended for residents of the United States. Click below to confirm you are a citizen and/or resident of the United States.

GO